Skip to Content

Join the 'Polycythemia Vera' group to help and get support from people like you.

Polycythemia Vera News

FDA Approves Jakafi (ruxolitinib) for Polycythemia Vera

Posted 4 Dec 2014 by Drugs.com

December 4, 2014 – The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition. Polycythemia vera occurs when too many red blood cells are made in the bone marrow. Patients may also experience an increase in white blood cells ...

Jakafi Approved for Chronic Bone Marrow Disease

Posted 4 Dec 2014 by Drugs.com

THURSDAY, Dec. 4, 2014 – Jakafi (ruxolitinib) has been approved by the U.S. Food and Drug Administration to treat polycythemia vera, a chronic disease of the bone marrow. Jakafi is the first FDA-sanctioned drug for the disease, which occurs when too many red blood cells are produced in the bone marrow. This may lead to a swollen spleen and phlebitis, characterized by blood clots near the surface ...

Ask a Question

Further Information

Related Condition Support Groups

Polycythemia

Related Drug Support Groups

hydroxyurea, ruxolitinib, Jakafi